Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

ABLYNX PROMOTED TO THE BELGIAN MID-CAP INDEX


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-02-20 18:08:46 -

GHENT,   Belgium,   20 February  2013 -  Ablynx  [Euronext  Brussels:  ABLX],  a
biopharmaceutical   company   engaged   in  the  discovery  and  development  of
Nanobodies®,  a  novel  class  of  therapeutic  proteins  based on single-domain
antibody  fragments for a  range of serious  human diseases, today announced its
promotion to the Belgian Mid-Cap Index (Bel Mid Index or BELMID). Ablynx will be
included in the BELMID Index as of the 18(th) of March 2013.

The entry of Ablynx to the BELMID Index is a result of performance of the Ablynx
shares  and is based on Ablynx's market capitalisation, free float and 
liquidity in the period up to end of January 2013. About Ablynx Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(®), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com. For more information, please contact Ablynx: Dr Edwin Moses Chairman and CEO t:   +32 (0)9 262 00 07 m: +44 (0)7771 954 193 /      +32 (0)473 39 50 68 e:  edwin.moses@ablynx.com Marieke Vermeersch Associate Director Investor Relations t:   +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e:  marieke.vermeersch@ablynx.com Follow us on Twitter @AblynxABLX M:Communications: Mary-Jane Elliott, Amber Bielecka, Claire Dickinson t:   +44 207 920 2330 e:  ablynx@mcomgroup.com press release in pdf format: hugin.info/137912/R/1679682/548575.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Ablynx via Thomson Reuters ONE [HUG#1679682]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser